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Abstract
The successful treatment of liver tumours is more likely if they are found early. The use of high-resolution CT and MRI
with contrast enhancement allows more sub-centimetre liver lesions to be detected, but some small tumours remain
occult even at surgery with intra-operative sonography. An indication of the accuracy of imaging in detecting liver
metastases may be given by the proportion of lesions found which are under 1–2 cm in size. The characterisation of
small lesions remains problematic on CT, with benign and malignant tumours showing overlapping imaging features.
However, with appropriate use of chemical shift, heavy T2 weighting, gadolinium enhancement, and liver-specific
contrast agents, a carefully tailored MRI examination will usually produce diagnostic appearances.
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Introduction
All tumours start out small, and treatment is more
effective if the disease is detected early; thus the current
focus of imaging is to improve our ability to recognise
small lesions. With colorectal liver metastases, careful
MRI or CT will detect 95% or more of lesions larger
than about 15 mm, and it is now uncommon for our
surgeons to discover lesions at the time of operation
that were not already detected by earlier imaging.
The real issue now is the accuracy of detection for
lesions smaller than this. The addition of intra-operative
ultrasound (IOUS) has improved our ability to find
small tumours, but in a current study in my own
department, 20% of patients undergoing liver resection
assisted by IOUS were found to have ‘new’ metastases
on follow-up within 6 months. Surgical findings at
laparotomy, even with IOUS, no longer represent an
adequate suitable standard of reference for measuring the
accuracy of imaging. One possible approach would be
to look at the distribution of sizes amongst the lesions
detected. A recent study [1] found that almost 60% of
colorectal liver metastases were smaller than 20 mm
at the time of detection, and 30% were smaller than
10 mm. If we can detect more lesions in this size range
we can be confident that our imaging techniques are
improving.
Once we have found a small lesion, we need to
determine whether it is benign or malignant. Small
(<15 mm) lesions discovered incidentally in patients
with no known primary malignancy are virtually always
benign [2,3], but in patients with known malignant disease
there are some metastases with CT appearances which
overlap with those of benign lesions [4]. Larger benign
lesions are less problematic on CT, but at all sizes the
MR appearances are more characteristic [5].
Liver cysts
Simple cysts are round unless deformed by more rigid
adjacent structures. Their contents are anechoic on
US, show water attenuation on CT, low signal on T1
MRI and high signal on T2 which is maintained on
heavily T2-weighted sequences. They are unchanged
after gadolinium—an enhancing rim suggests necrotic
metastasis, or in the appropriate clinical context, abscess.
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Haemangiomas
Characteristically, haemangiomas are hyper-echoic on
sonography, show geographic shape with low attenuation
on unenhanced CT and on T1-weighted MRI. Their high
signal on conventional T2-weighted MRI is maintained
with more heavy T2 weighting (TE = 180 m/s, or
HASTE). With contrast-enhanced CT or gadolinium-
enhanced MRI, the lesions show nodular enhancement
at the periphery, followed by centripetal infilling over
the next 5–10 min. The discontinuity of the peripheral
nodular enhancement is a specific feature, and peripheral
wash-out does not occur. In contrast, metastases with
necrotic centres are usually round in shape and although
they may show peripheral enhancement, the ring is
more uniform. Whilst delayed enhancement of the
necrotic centre of metastases is not uncommon, the
brightly enhancing peripheral ring fades fairly rapidly.
Some small haemangiomas show uniform and rapid
enhancement starting in the arterial phase, similar to
small hepatocellular lesions, but they usually show
intensely bright signal on T2-weighted MRI, in contrast
to the iso-intense or mildly hyper-intense appearance
of small benign hepatocellular lesions. Other atypical
haemangiomas include small lesions with centrifugal
enhancement from a single vascular nodule (central dot
sign) and in other cases the lesion may be predominantly
fibrous, so enhancement is patchy and delayed, with little
of the typical peripheral nodular vascularity.
Fatty change
Fatty infiltration is often heterogeneous, sometimes focal,
and in other cases small focal areas of liver parenchyma
may be spared from fatty change. On sonography, either
focal fatty change or focal sparing can produce lesions
which are difficult to distinguish from metastases. One
helpful feature with focal fatty change or sparing is that
there is usually no mass effect—vessels run normally
through the apparently abnormal areas. Focal fat may be
recognisable on CT by its geographic distribution, normal
contrast enhancement, and the lack of a mass effect, but a
more reliable diagnosis can be made on MRI. In patients
with diffuse fatty change, metastases may be obscured
on CT because their low attenuation is matched by the
low attenuation of the surrounding liver. Occasionally, a
ring of liver tissue immediately surrounding the lesion
may be spared from fatty change, producing an irregular
halo of denser tissue within an otherwise homogeneous
liver. This appearance can be seen with haemangiomas
in a fatty liver, as well as with metastases. Using in-
phase and opposed-phase T1 sequences, MRI offers a
rapid and reliable approach for the recognition of focal
fat, and reveals metastatic lesions in the diffusely fatty
liver. Where any diagnostic doubt remains, liver specific
contrast agents may be given.
Focal nodular hyperplasia (FNH)
With the widespread use of dual-phase CT, multi-
phase contrast-enhanced MR, and the recent introduction
of vascular contrast agents in sonography, has come
a realisation that FNH is not rare. Larger lesions
typically show a rounded or lobulated shape with clear-
cut margin, a mass effect displacing adjacent vessels,
and a central scar sometimes with radiating spokes
towards the periphery. Their echogenicity, attenuation
and signal characteristics are little different to those of
normal liver tissue. The lesions show marked arterial
phase contrast enhancement which usually fades rapidly
to become iso-intense in the portal phase, although
occasionally increased enhancement lasts for several
minutes. Delayed enhancement of the central scar is
characteristic. Lesions smaller than about 2 cm are often
homogeneous with no central scar, but show the same
enhancement characteristics. It is not rare for these small
lesions to be multiple, and they may co-exist with other
benign lesions. When found in patients with known
malignancy, a confident diagnosis of FNH requires the
demonstration of intact liver function within the lesion.
The most effective method is to use superparamagnetic
iron oxide (SPIO) enhancement. Some FNH lesions will
take up as much SPIO as normal liver, so the lesion
appears black on the post-contrast T2-weighted images.
In other cases the lesion may take up some SPIO, but
less than the surrounding liver, so that the lesion becomes
more apparent after contrast. In these cases it is important
to use the same T2-weighted sequence before and after
SPIO, and measure the change in signal intensity in
both liver and lesion. If the lesion shows substantial
SPIO uptake (more than 40–50% reduction in signal),
it may be regarded as benign. Metastases do not take
up SPIO, but well differentiated hepatocellular cancers
may take up a little. Another approach is to use one
of the hepatocellular MR contrast agents (mangafodipir,
gadobenate, or gadoxetic acid). All of these agents are
taken up by the functioning hepatocytes present in FNH
lesions (and also in well differentiated HCC), but because
there is no biliary excretory pathway, the lesions retain
the contrast for much longer than the normal liver, so
becoming brighter than liver on delayed T1-weighted
images.
Focal perfusion artefacts
Peripheral wedge-shaped areas of abnormal perfusion,
usually seen only in the arterial dominant phases of
enhanced CT and MRI, are probably caused by segmental
portal vein occlusion which in some cases is associated
with parenchymal tumour deposits, but in other cases no
cause can be found. Such transient hepatic attenuation de-
fects (THADs) may also be associated with parenchymal
oedema within the liver which appears hyper-intense on
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T2-weighted MRI. Around the periphery of segment 4,
particularly just to the right of the falciform ligament
anteriorly, and also anterior to the bifurcation of the portal
vein, small areas of liver parenchyma may receive non-
portal venous supply from the parabiliary venous plexus
and from anomalous drainage of gastric, duodenal and
pancreatic veins. This can produce small nodules of focal
fatty change in these areas, or more commonly may result
in small areas of altered enhancement after contrast.
Other benign malformations
Biliary microhamartomas (von Meyenburg complexes)
show imaging characteristics which overlap between
cysts and haemangiomas. These biliary malformations
are often irregular or even angular in shape, and usually
only a few millimetres in diameter.
Conclusions and key points
Incidental small benign lesions are relatively common
in patients with malignant disease, and must be dis-
tinguished from metastatic disease in order to avoid
erroneous management.
Focal fat, focal sparing and haemangiomas may be
diagnosed on sonography or CT if they are typical,
but in other cases MRI is usually decisive. FNH
can be diagnosed with confidence using liver-specific
MR contrast agents. Discriminating small cysts and
haemangiomas from metastases is best done with MRI
using a heavily T2-weighted sequence followed by
dynamic gadolinium-enhanced T1. Tiny lesions which
appear on CT to have an angular shape and low
attenuation will usually be biliary microhamartomas.
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